Abilify (aripiprazole) is a psychotropic drug ( antipsychotic) that alters brain chemical activity used to treat: schizophrenia, mania, depression, bipolar disorders, autistic disorder, and some irritable behavior disorders
Aripiprazole (Abilify) is an atypical antipsychotic used to treat different mental health conditions, such as schizophrenia and bipolar I disorder
Generic name: ARIPIPRAZOLE 2mg Dosage form: tablet, oral solution, orally disintegrating tablet, injection Drug class: Atypical antipsychotics Medically
Aripiprazole is an antipsychotic medicine that is used to treat schizophrenia in adults and children at least 13 years old
Abilify can't treat agitation due to Alzheimer's disease
VIP Lounge at Varadero Airport 6:14 pm
The objective of this
Abilify is an anti-psychotic medication used to treat several different conditions — schizophrenia, bipolar disorder, depression and anxiety — in adults
Click to Read 9 Comments & Reviews 💬
Aripiprazole is also used with an antidepressant to treat depression when symptoms cannot be controlled by the antidepressant alone
dose 50% in poor CYP2D6 metabolizers; periodically reassess need for
ABILIFY MAINTENA ® (aripiprazole) is a prescription medicine given by injection by a healthcare professional for: treatment of schizophrenia in adults
DONATE NOW
55% of reviewers reported a positive experience, while 30% reported a
Abilify, or the generic form, aripiprazole, is an antipsychotic drug that treats symptoms of mental health disorders like bipolar disorder and schizophrenia
This is called dementia-related psychosis, and it shouldn't be treated with Abilify Maintena (aripiprazole)
Trials with oral aripiprazole have shown that, compared with some other atypical antipsychotics, aripiprazole is associated with fewer metabolic disturbances and has a favourable cardiovascular tolerability profile
2 out of 10 from a total of 99 reviews for the treatment of Schizophrenia
Schizophrenia is a mental health condition that often involves people hearing voices or feeling as though others are out to get them
In studies, somnolence (hypersomnia, sedation, and somnolence) was reported in 7% of patients treated with Vraylar compared to 6% of placebo-treated patients